Comparative Pharmacology
Head-to-head clinical analysis: DILOR 400 versus THEOPHYL SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR 400 versus THEOPHYL SR.
DILOR-400 vs THEOPHYL-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing cyclic AMP levels, and antagonizes adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
300 mg orally every 12 hours, with dosing titrated to achieve serum trough concentrations of 5-15 mcg/mL.
None Documented
None Documented
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Adults: 8-10 hours (range 3-12); Neonates: 20-30 hours; Smokers: 4-5 hours; Cirrhosis: 30-40 hours. Dose adjustments needed based on half-life variations.
Renal (70% unchanged), hepatic metabolism (30%)
Renal: ~10% unchanged; Hepatic metabolism (90%) via CYP1A2, 3A4; metabolites (caffeine, 3-methylxanthine) excreted renally. Total clearance predominantly hepatic.
Category C
Category C
Bronchodilator
Bronchodilator